199 related articles for article (PubMed ID: 25833960)
1. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
Nonami A; Sattler M; Weisberg E; Liu Q; Zhang J; Patricelli MP; Christie AL; Saur AM; Kohl NE; Kung AL; Yoon H; Sim T; Gray NS; Griffin JD
Blood; 2015 May; 125(20):3133-43. PubMed ID: 25833960
[TBL] [Abstract][Full Text] [Related]
2. Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine.
Qian L; Chen K; Wang C; Chen Z; Meng Z; Wang P
Clin Cancer Res; 2020 Jul; 26(13):3408-3419. PubMed ID: 32156748
[TBL] [Abstract][Full Text] [Related]
3. First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.
Cho H; Shin I; Ju E; Choi S; Hur W; Kim H; Hong E; Kim ND; Choi HG; Gray NS; Sim T
J Med Chem; 2018 Sep; 61(18):8353-8373. PubMed ID: 30153003
[TBL] [Abstract][Full Text] [Related]
4. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
5. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Vujic I; Sanlorenzo M; Posch C; Esteve-Puig R; Yen AJ; Kwong A; Tsumura A; Murphy R; Rappersberger K; Ortiz-Urda S
Oncotarget; 2015 Jan; 6(2):969-78. PubMed ID: 25504439
[TBL] [Abstract][Full Text] [Related]
6. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.
Hayes TK; Luo F; Cohen O; Goodale AB; Lee Y; Pantel S; Bagul M; Piccioni F; Root DE; Garraway LA; Meyerson M; Johannessen CM
Cancer Res; 2019 May; 79(9):2352-2366. PubMed ID: 30819666
[TBL] [Abstract][Full Text] [Related]
7. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
Posch C; Cholewa BD; Vujic I; Sanlorenzo M; Ma J; Kim ST; Kleffel S; Schatton T; Rappersberger K; Gutteridge R; Ahmad N; Ortiz/Urda S
J Invest Dermatol; 2015 Oct; 135(10):2475-2483. PubMed ID: 26016894
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
9. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
[TBL] [Abstract][Full Text] [Related]
10. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
11. Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.
Park S; Kim TM; Cho SY; Kim S; Oh Y; Kim M; Keam B; Kim DW; Heo DS
Cancer Lett; 2020 Dec; 495():135-144. PubMed ID: 32979462
[TBL] [Abstract][Full Text] [Related]
12. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
13. Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
Kiessling MK; Curioni-Fontecedro A; Samaras P; Lang S; Scharl M; Aguzzi A; Oldrige DA; Maris JM; Rogler G
PLoS One; 2016; 11(1):e0147682. PubMed ID: 26821351
[TBL] [Abstract][Full Text] [Related]
14. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation.
Takashima A; English B; Chen Z; Cao J; Cui R; Williams RM; Faller DV
ACS Chem Biol; 2014 Apr; 9(4):1003-14. PubMed ID: 24506253
[TBL] [Abstract][Full Text] [Related]
16. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
17. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract][Full Text] [Related]
18. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.
Mao X; Cao B; Wood TE; Hurren R; Tong J; Wang X; Wang W; Li J; Jin Y; Sun W; Spagnuolo PA; MacLean N; Moran MF; Datti A; Wrana J; Batey RA; Schimmer AD
Blood; 2011 Feb; 117(6):1986-97. PubMed ID: 21135258
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
20. RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.
Laugier F; Finet-Benyair A; André J; Rachakonda PS; Kumar R; Bensussan A; Dumaz N
Oncotarget; 2015 Sep; 6(29):28120-31. PubMed ID: 26356562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
